Skip to main navigation

Skip to content

Careers
Contact Us
中文

Home
About
Research & Development
- Pipeline
- Technology Platforms
Therapies
Newsroom
Investors

Careers
Contact Us
中文

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Mar 19, 2024

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

Mar 15, 2024

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Mar 11, 2024

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

Feb 23, 2024

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

Feb 13, 2024

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

Jan 03, 2024

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Jan 02, 2024

Legend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 27 of 27

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY POLICY
LEGAL NOTICE
CONTACT US
SITE MAP

© 2024 Legend Biotech. All rights reserved. dedication

You are about to leave Investors.LegendBiotech.com